An interventional study of BiPAP and CPAP in Asthma Acute and Asthma in Children, sponsored by University of British Columbia. Status unknown. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-05-02.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.
Among the 20 studies in Asthma by University of British Columbia, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2018, is one of 11 with no phase, and was the 11th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages up to 6 mo · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 18–55 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 19–49
University of British Columbia · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 52 across the 14 interventional studies, 511 across the 6 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
1 of the studies in Asthma by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653347University of British ColumbiaInfant RSV Immunity Study | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Asthma by University of British Columbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute asthma produces greatly increased work of breathing and increased oxygen requirement secondary to bronchial narrowing and airway obstruction by inflammatory secretions. There is growing evidence that non-invasive ventilation can reverse these processes more efficiently than conventional asthma therapy. Surprisingly, there have not yet been any large scale prospective controlled studies to investigate this hypothesis, (either in adults or children). Consequently, the aim of this study is to determine if the use of non-invasive positive airway pressure, for children admitted to hospital with an acute exacerbation of asthma, reduces their work of breathing, need for adjunctive medications, and shortens the length of hospital stay, compared to current standard therapy.
The aim of the study is to determine if the use of NIV, for children admitted to hospital with an acute exacerbation of asthma, reduces their work of breathing, need for adjunctive medication, length of hospital stay, and need for intubation and mechanical ventilation. Study design will be prospective, randomized and controlled. The tightly fitting face mask necessary for NIV makes it impossible to make this a blinded study.
The principal enrollment criteria will be children over 2 years of age presenting to the ER with acute asthma. After diagnosis, all children are treated with standard therapy (systemic steroids plus 3 doses of inhaled salbutamol and 1 dose of inhaled ipratropium over a 1 hour period then hourly salbutamol). The principal decision between discharge track and admission track will be made at 2 hours after first steroid dose. Admission criteria are based on sequential PRAM scores.
After initial asthma treatment and observation in the emergency room, to determine which patients can be discharged home, those who need admission will be asked to join the study, then consented and randomized. There will be three treatment groups:
All children will be admitted to a small 3 bed respiratory unit. They will be closely monitored and objectively scored every 4 hours using the PRAM asthma clinical severity score (Pediatric Respiratory Assessment Measure). Projected patient enrollment will be at least 30 in each arm. Estimated study duration is 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 \> 92%.
Drug: Ipratropium · Drug: Magnesium Sulfate · Drug: Aminophylline · Drug: Standard steroid dose, hourly salbutamol, oxygen as needed
Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 \> 92%.
Device: CPAP · Drug: Standard steroid dose, hourly salbutamol, oxygen as needed
Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
Device: BiPAP · Drug: Standard steroid dose, hourly salbutamol, oxygen as needed
The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
Also known as: Trilogy BiPAP, Bilevel Positive Airway Pressure
The patient breathes against a constant pressure delivered by face mask.
Also known as: Continuous Positive Airway Pressure
Nebulized q6h
50mg/kg IV, 4 doses q6h
6mg/kg IV (if no progress)
Standard common therapies for all three arms.
Time to reach a PRAM score of ≤3
PRAM score includes assessment of oxygen saturations, suprasternal retractions, scalene muscle contraction, air entry and wheezing.
Time frame: Patients will be followed for the duration of their hospital stay (an estimated average duration of 4 days)
Time to room air
Time that oxygen is required
Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).
Total medication use per 12 hr period
Comparison of total medication use by children in each arm.
Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).
Numbers failing treatment and transferred to ICU
Number of patients in each group that fail treatment and require transfer to ICU
Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).
Time to reach FEV1 >80% predicted in those children able to perform pulmonary function tests
Standard pulmonary function tests can usually be performed by children \>6 years.
Time frame: Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Jun 2018; primary completion for Nov 2018, 5 months later.
Of 600 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 5 months is below that.
Counting every sponsor, half of 650 studies reached it within 23 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →